Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13181100 | 0.88 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL13153132 | 0.83 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL9908393 | 0.83 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL12017401 | 0.82 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL18507345 | 0.81 | CYP3A4 (0.48) | L3MBTL1CYP11B1ERCC5KLKB1KDM5B | |
| SCHEMBL12068737 | 0.80 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL14804462 | 0.79 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL12070826 | 0.79 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL30027790 | 0.79 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 | |
| SCHEMBL29160059 | 0.79 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1PKMCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096928-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-8962596-B2 | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | ARRAY BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | L3MBTL1 822/4885ALDH1A1 2487/4885PKM 1182/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | L3MBTL1 3982/4885ALDH1A1 2036/4885PKM 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.